#### LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCK. O. 259 181

SERIAL NO.

APPLICANT:

Malcom R. Alison; Charles Contelle: Stuart J. Forbes; Humphrey J.F. Hodgson; Ildiko Sarosi; Michael Themis

FILING DATE:

GROUP:

U.S. PATENT DOCUMENTS							
EXAMINER INDIAN	: :	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILIKG DATE
BS	AA	5,650,504	07/22.97	Bartley, Timothy D., et al.	536	23.5	05 24 95
	AB	5,712,163	1/27/98	Parenteau, et al.	4354	405	
	AC	5,716,934	02/10/98	Bartley, Timothy D., et al.	5)4	<b>12</b>	05.30.95
	AD	5.814,605	09/29/98	Pierce, Glenn Francis, et al.	51460	52	06/06/95
	AE	5,824,303	10/20/98	Bartley, Tomothy D., et al.	424 =	94.5	05/19/95
	ΛF	5,824,643	10/20/98	Pierce, Glenn Francis, et al.	514	12	06/07/95
D18	AG	5,858.977	01/12/99	Aukerman. Sharon Lea	514	12	04/11/97
	AH	5,900,404	05/04/99	Gegg. Colin. et al.	514	12	08/15/97

			FOREIG	N PATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
B	Al	WO96/11949	4/25/96	PCT	1		
8	ΑJ	WO96/11951	4/25/96	PCT			
08	AK	W098/24813	6/11/98	PCT		<b>I</b>	

	-	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
18	AL	Andreadis, et al., Cell Cycle Dependence Of Retroviral Transduction: An Issue of overlapping time scales, Biotechnology and Bioengineering 58:272-281 (1998)
	ΑМ	Angervo M, et al., Tri-iodothyronine and cycloheximide enhance insulin-like growth factor-binding protein-1 gene expression in human hepatoma cells, J. Mol. Endocrinol. 10(1):7-13 (1993)
	AN	Batshaw, Inborn errors of urea synthesis. Ann. Neurol. 35(2):133-141 (1994)
	лО	Bieniasz PD, et al., Cell cycle dependence of foamy retrovirus infection, J. Virol. 69(11):7295-9 (1995)
	ΑP	Bosch A, et al., Proliferation induced by keratinocyte growth factor enhances in vivo retroviral-mediated gene transfer to mouse hepatocytes, J. Clin. Invest. 98(12):2683-7 (1996)
	AQ	Bowling WM, et al., Portal branch occlusion safely facilitates in vivo retroviral vector transduction of rat liver, Hum. Gene Ther. 7(17):2113-21 (1996)
PS	AR	Branchereau S, et al., Factors influencing retroviral-mediated gene transfer into hepatocytes in vivo, Hum. Gene Ther. 5(7):803-8 (1994)
1A-173198 1		DATE CONSIDERED.

EXAMINER:

DATE CONSIDERED:

5/6/04

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

Information Disclosure Statement - Section 9 PTO-1449

# LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKE O.

SERIAL NO.

259:181

APPLICANT:

Malcom R. Alison; Charles Contelle; Stuart J. Forbes; Humphrey J.F. Hodgson; Ildiko Sarosi; Michael Themis

FILING DATE:

GROUP:

00		Canzanelli, et al., Control of liver regeneration and nucleic acid content by the thyroid: with the observations on the effects of pyrimidines, Am.J.Physiol. 157:225-229 (1949).
P>	AS	Cardoso, et al., In situ retrovirus-mediated gene transfer into dog liver, Human Gene Therapy 4:411-418 at 412
ſ	A TE	
	AT	(1993)
į į	АU	Chang and Wu, Gene therapy: applications to the treatment of gastrointestinal and liver diseases, Gastroenterology 106:1076-1084 (1994)
i		Choo KH, et al., Molecular cloning of the gene for human anti-haemophilic factor IX, Nature. 299(5879):178-80
	AV	(1982)
		Clarke DJ, et al., Genetic defects of the UDP-glucuronosyltransferase-1 (UGT1) gene that cause familial non-
1	AW	haemolytic unconjugated hyperbilirubinaemias, Clin. Chim. Acta 266(1):63-74 (1997)
		Cosset FL, et al., High-titer packaging cells producing recombinant retroviruses resistant to human serum, J. Virol.
, 4	AX	69(12):7430-6 (1995)
		Demori I, et al., Tri-iodothyronine increases insulin-like growth factor binding protein-4 expression in rat
128	ΑΥ	hepatocytes, J. Endocrinol. 154(1):155-65 (1997)
Already	20	
record	AZ	Dayern et al. Gene therapy for liver disease. Dig. Dis. 16.23-37 (1998)
(20)		Eisensmith & Woo, Somatic gene therapy for phenylketonuria and other hepatic deficiencies, J. Inher. Metab. Dis.
WS_	BA	19:412-423 (1996)
		Ferry N, et al., Retroviral-mediated gene transfer into hepatocytes in vivo, Proc. Nat'l Acad. Sci. U.S.A.
L	BB	88(19):8377-81 (1991)
1	D.O.	United State 1 (1992)
<u> </u>	BC	Ferry & Heard, Liver-directed gene transfer vectors, Human Gene Ther. 9:1975-1981 (1998)
ļ \	BD	Fisher, et al., Recombinant adeno-associated virus for muscle directed gene therapy. Nat. Med. 3:306-312 (1997)
		Forbes and Hodgson, Review article: gene therapy in gastroenterology and hepatology, Aliment. Pharmacol. Ther.
i \	BE	11:823-836 (1997)
		Forbes SI, et al., Retroviral gene transfer to the liver in vivo during tri-iodothyronine induced hyperplasia, Gene
	BF	Ther. 5(4):552-5 (1998)
		Francavilla A, et al., Hepatocyte proliferation and gene expression induced by triiodothyronine in vivo and in vitro.
	BG	Hepatology 20(5):1237-41 (1994)
	(	Horsthemke B, et al., Identification of a deletion in the low density lipoprotein (LDL) receptor gene in a patient
	BH	with familial hypercholesterolaemia. Hum. Genet. 71(1):75-8 (1985)
		Horwich, Inherited hepatic enzyme defects as candidates for liver-directed gene therapy, Curr. Top. Microbiol.
	BI	Immunol 168:185-200 (1991)
1 1	D.	Housley RM, et al., Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout
\\-	BJ	the rat gastrointestinal tract, J. Clin. Invest. 94(5):1764-77 (1994)  Hudig F, et al., Tri-iodothyronine prevents the amiodarone-induced decrease in the expression of the liver low-
1	DIV	
·	BK	density lipoprotein receptor gene, J. Endocrinol. 152(3):413-21 (1997)  Ill, Charles R. et al., Optimization of the human factor VIII complementary DNA expression plasmid for gene
i I	10	therapy of hemophilia A, Blood Coagulation and Fibrinolysis, Vol. 8, Suppl. 2, 1997
<del></del>	BL	Kay, et al., Hepatic gene therapy: persistent expression of human alpha 1-antitrypsin in mice after direct
1	BM	gene delivery in vivo. Human Gene Therapy 3:641-647 at 642 (1992)
-	1	Kitraki E, et al., Hormonal control of insulin-like growth factor-II gene expression in the rat liver, J. Mol.
	BN	Endocrinol. 9(2):131-6 (1992)
to	=	Knaan-Shanzer S, et al., Cell cycle state, response to hemopoietic growth factors and retroviral vector-mediated
100	во	transduction of human hemopoietic stem cells, Gene Ther. 3(4):323-33 (1996)

LA-173198.1	DATE CONSIDERED:
EXAMINER:	
1) July en	5/6/04

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

# LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKE O

SERIAL NO.

259 181

APPLICANT:

Malcom R. Alison; Charles Coutelle; Stuart J. Forbes; Humphrey J.F. Hodgson; Hdiko Sarosi; Michael Themis

FILING DATE:

GROUP:

DS	BP	Kosai KI, et al., Retrovirus-mediated in vivo gene transfer in the replicating liver using recombinant hepatocyte growth factor without liver injury or partial hepatectomy, Hum. Gene Ther. 9(9):1293-301 (1998)
	BQ	Li, et al., In vivo gene therapy for hyperlipidemia: phenotypic correction in Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene, J. Clin, Invest. 95:768-773 (1995)
	BR	Lieber A, et al., Adenovirus-mediated urokinase gene transfer induces liver regeneration and allows for efficient retrovirus transduction of hepatocytes in vivo, Proc. Nat'l Acad. Sci. U.S.A. 92(13):6210-4 (1995)
	BS	Lieber A, et al., A modified urokinase plasminogen activator induces liver regeneration without bleeding. Hum. Gene Ther. 6(8):1029-37 (1995)
	BT	Mann, et al., Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.  Cell 33:153-159 (1983)
	BU!	Oinonen T, et al., Hormonal regulation of the zonated expression of cytochrome P-450 3A in rat liver, Biochem. J. 309 (Pt 1):55-61 (1995)
	BV	Ott, et al., Simultaneous up-regulation of viral receptor expression and DNA synthesis is required for increasing efficiency of retroviral hepatic gene transfer. J. Biol. Chem. 273(19):11954-61 (1998)
	BW	Reich-Slotky R, et al., Chimeric molecules between keratinocyte growth factor and basic fibroblast growth factor define domains that confer receptor binding specificities, J. Biol. Chem. 270(50):29813-8 (1995)
	BX	Rettinger SD, et al., In vivo hepatocyte transduction with retrovirus during in-flow occlusion, J. Surg. Res. 54(5):418-25 (1993)
	BY	Roe, et al., Integration of murine leukemia virus DNA depends on mitosis, EMBO J. 12:2099-2108 (1993)
	BZ	Rusch, Sharyn L., et al., Protein transport via amino-terminal targeting sequences: common themes in diverse systems (Review), Molecular Membrane Biology 12, 295-307 (1995)
	CA	Sandig and Strauss, Liver-directed gene transfer and application to therapy, J. Mol. Med. 74:205-212 (1996)
	СВ	Shima N, et al., Hepatocyte growth factor and its variant with a deletion of five amino acids are distinguishable in their biological activity and tertiary structure, Biochem, Biophys. Res. Commun. 200(2):808-15 (1994)
	CC	Stolz DB, et al., Comparative effects of hepatocyte growth factor and epidermal growth factor on motility, morphology, mitogenesis, and signal transduction of primary rat hepatocytes, J. Cell. Biochem. 55(4):445-64 (1994)
	CD	Strain AJ, et al., Native and recombinant human hepatocyte growth factors are highly potent promoters of DNA synthesis in both human and rat hepatocytes, J. Clin. Invest. 87(5):1853-7 (1991)
	CE	Von Heijne, Gunnar, Signal Sequences, The Limits of Variation, J. Mol. Biol. (1985) 184, 99-105
T	CF	Zarnegar R, et al., Expression of hepatocyte growth factor mRNA in regenerating rat liver after partial hepatectomy, Biochem, Biophys. Res. Commun. 177(1):559-65 (1991)
B	CG	Zhang, WW., Antisense oncogene and tumor suppressor gene therapy of cancer, J. Mol. Med. 74:191-204 (1996)

i &A-173198.1	DATE CONSIDERED:
EVALABLER	DATE CONSIDERED.
EXAMINER:	-10.000
	5/6/24
l	

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

# LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCK. 10.

SERIAL NO.

259-181

APPLICANT:

Malcom R. Alison: Charles Coutelle: Surart J. Forbes: Humphrey J.F. Hodgson: Ikhko Sarosi: Michael Themis

FILING DATE:

GROUP:

	1	
DS	CIL	Alberts, et al., Molecular Biology Of The Cell, 2d Edition, pp. 961-2.
		Bosch, et al., Effects of keratinocyte and hepatocyte growth factor in vivo: implications for retrovirus-mediated
CI		gene transfer to liver, Hum Gene Ther 9(12):1747-54 (1998).
·	<del></del>	
CJ Cabrera, et al., Targetec		Cabrera, et al., Targeted retroviral gene transfer into the rat biliary tract, Somat Cell Mol Genet, 22(1):21-9 (1996).
1		Cai et al.; "Therapeutic Levels of Human Protein C in Rats after Retroviral Vector-medicated Hepatic Gene
	CK	! Therapy"; The American Society for Clinical Investigation, Inc., Vol. 101, No. 12, June 1998, pp. 2831-2841
	CL	Crystal, R.G. Transfer of Genes to Humans: Early Lessons and Obstacles to Sucess. Science 270:404-410.
		Deonarain, M.P. Ligand-targeted receptor-mediated vectors for gene delivery. Exp. Opin. Ther. Patents 8(1):53-
	CM	69.
		Forbes S J et al.; "Tri-iodothyronine and dHGF synergistically enhance hepatocyte DNA synthesis in vivo and
1		enable peripheral venous strategies for retroviral gene transfer." HEPATOLOGY, vol. 28, no. 4 PART 2, October
1		1998 (1998-10), page 503A XP000946022; Biennial Scientific Meeting of the International Association for the
	1	Study of the Liver and the 49th Annual Meeting and Postgraduate Courses of the American Association for the
	CN	Study of Liver Diseases; Chicago, Illinois, USA; November 4-10, 1998; ISSN: 0270-9139 abstract
<del> </del>	1	Forbes S J et al.: "Retroviral gene transfer to the liver in vivo without prior partial hepatectomy." CLINICAL
, I	i	SCIENCE (London), vol. 94, no. 2, February 1998 (1998-02), page 2P XP000946045; Meeting of the Medical
)	CO	SCIENCE (London), vol. 94, no. 2, reolumy 1998 (1998-02), page 2P XP000940045; Meeting of the Medical
	CO	Research Society; London, England, UK; November 13-14, 1997; ISSN: 0143-5221 abstract
	2 00	
Al	CP	Forbes et al., Gastroenterology, Vol. 118, pages 591-598.
Mirecon	0+	Fujimoto, "Hepatology: Microcirculation and Pathogenesis of Alcoholic Liver Injury Gene therapy for liver
recover	CQ	cirrhosis": Johnnal-of-Gastroenterology and Hepatology (2000) "IS" (Suppl") pp. D33_D36:
	ļ	Gerolami et al.; "Evaluation of HSV-tk Gene Therapy in a Rat Model of Chemically Induced Hepatocellular
1		Carcinoma by Intratumoral and Intrahepatic Artery Routes; Cancer Research February 15, 2000, Vol. 60, No. 4,
	CR	pp. 779-1152
		Grove et al., "Pre-clinical trials using hepatic gene delivery", Advanced Drug Delivery Reviews 30 (1998) pp.
<b>!</b>	CS	199-204
		Kolodka et al.; "Gene therapy for diabetes mellitus in rats by hepatic expression of insulin"; Proc. Natl. Acad. Sci.
	CI	USA, Vol. 92, April 1995, Medical Sciences, pp. 3293-3297
	1	Kalodka et al.; "Hepatic Gene Therapy: Efficient Retroviral-Mediated Gene Transfer into Rat Hepatocytes In
	CU	Vivo"; Somatic Cell and Molecular Genetics, Vol. 19, No. 5, 1993, pp. 491-497
	1	Le et al., "Therapeutic Levels of Functional Human Factor X in Rats After Retroviral-Mediated Hepatic Gene
	CV	Therapy"; Blood, Vol. 89, No. 4 (February 15), pp. 1254-1259
<del>  -</del>	100	
	CW	Ledley et al.; "Retroviral gene transfer into primary hepatocytes: Implications for genetic therapy of liver-specific
	1011	functions": Proc. Natl. Acad. Sci. USA, Vol. 84, August 1987, Genetics, pp. 5335-5339
.		Lucey et al., "Minimal criteria for placement of adults on the liver transplant waiting list; a report of a national
		conference organized by the American Society of Transplant Physicians and the American Association for the
CX Study of Liver Diseases"; Liver Transplantation and Surgery, Vol 3, 62		Study of Liver Diseases"; Liver Transplantation and Surgery, Vol 3, 628-637
:	!	
	<u>, C7.</u>	Miller et al. Targeted vectors for gene therapy. FASEB J. 9:190-199.
2		Murphy, G.P. et al. American Cancer Society Textbook of Clinical Oncology, Second Edition. The American
	·   CZ	Cancer Society Inc., Atanta.

[ LA-173198.1	DATE CONSIDERED:
EXAMINER: DELOQ	5/6/04
EXAMINER: Initial if reference is considered, whether	or not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and	
communication to applicant	

# LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCK O.

SERIAL NO.

259/181

APPLICANT:

Malcom R. Alison, Charles Coutelle; Stuart J. Forbes; Humphrey J.F. Hodgson; Ildiko Sarosi; Michael Themis

FILING DATE:

GROUP:

Pakkanen, et al., Improved gene transfer efficiency in liver with vesicular stomatitis virus G-protein pseudotyped retrovirus after partial liver resection and thymidine kinase-ganciclovir pre-treatment, Pharmacol Res. 40(5):451-7 (1999).  Pakkanen, et al., Enhanced plasma cholesterol lowering effect of retrovirus-mediated LDL receptor gene transfer to WHHL rabbit liver after improved surgical technique and stimulation of hepatocyte probleration by combined partial liver resection and thymidine kinase-ganciclovir treatment. Gene Ther. 6(1):34-41 (1999)  Quet al.; "Blockade of type B transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat"; Proc. Natl. Acad. Sci. USA, Vol. 96, March 1999, Medical Sciences, pp. 2345-2349  Remington's Pharmaceutical Services. Mack Publishing Company: Easton, PA. 18th Edition, pages 1303, 1304. and 1571.  Ruiz et al.; "Gene therapy of viral hepatitis and hepatocellular carcinoma", Journal of Viral Hepatitis, 1999, 6, pp. 17-34  Themis M. et al. Enhanced in vitro and in vivo gene delivery using cationic agent completed retrovirus vectors, Gene Ther. 1998 Sept; 5(9):1180-6  Lichi et al., "Mepatocyne growth factor gene therapy of liver circlosis in rate", 1999 Nature Amorica Inc., Vol. 5.  Np. 2-February 1999, pp. 226-230  Verma LM-et al. Gene therapy - promises, problems and prospects. Nature 389/239-242.	DX2	F	Orkin, S.H. et al. Report and Recommendation of the Panel to Ass	ess the NIH Investment in Research on Gene
tetrovirus after partial liver resection and thymidine kinase-ganciclovir pre-treatment, Pharmacol Res. 40(5):451-7 (1999).  Pakkanen, et al., Enhanced plasma cholesterol lowering effect of retrovirus-mediated LDL receptor gene transfer to WHHL rabbit liver after improved surgical technique and stimulation of hepatocyte proliferation by combined partial liver resection and thymidine kinase-ganciclovir treatment. Gene Ther. 6(1):34-31 (1999)  Qi et al.; "Blockade of type β transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat"; Proc. Natl. Acad. Sci. USA, Vol. 96, March 1999, Medical Sciences, pp. 2345-2349  Remington's Pharmaceutical Services, Mack Publishing Company: Easton, PA, 18th Edition, pages 1303, 1304, and 1571.  Ruiz et al.; "Gene therapy of viral hepatitis and hepatocellular carcinoma", Journal of Viral Hepatitis, 1999, 6, pp. 17-34  Themis M, et al. Enhanced in vitro and in vivo gene delivery using cationic agent completed retrovirus vectors, Gene Ther. 1998 Sept; 5(9):1180-6  Lucki et al., "Hepataeva growth factor gene therapy of liver circhosis in-rate", 1990-Nature Amorica Inc., Natl. 5. Np. 2-February-1999-pp. 226-230  Verma LM-et al. Gene therapy - promises, problems and prospects. Nature 389:239-242.	123	DA	Therapy. National Institute of Health. Bethesda, Maryland.	
DB (1999).  Pakkanen, et al., Enhanced plasma cholesterol lowering effect of retrovirus-mediated LDL receptor gene transfer to WHHL rabbit liver resection and thymidine kinase—ganciclos in treatment. Gene Ther. 6(1):34-41 (1999)  Qi et al.; "Blockade of type β transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat"; Proc. Natl. Acad. Sci. USA, Vol. 96, March 1999, Medical Sciences, pp. 2345-2349  Reminigton's Pharmaceutical Services, Mack Publishing Company: Easton, PA. 18th Edition, pages 1303, 1304. and 1571.  Ruiz et al.; "Gene therapy of viral hepatitis and hepatocellular carcinoma", Journal of Viral Hepatitis, 1999, 6, pp. 17-34  Themis M. et al. Enhanced in vitro and in vivo gene delivery using cationic agent completed retrovirus vectors, Gene Ther. 1998 Sept; 5(9):1180-6  Leki et al., "Hepatocyte growth factor gene therapy of liver circlinesis in rate", 1999 Nature Amosica Inc., Mal. 5. Np. 2-February. 1999, pp. 226-230  Verma LAM-et al. Gene therapy - promises, problems and prospects. Nature 389:239-242.		1		
Pakkanen, et al., Enhanced plasma cholesterol lowering effect of retrovirus-mediated LDL receptor gene transfer to WHHL rabbit liver after improved surgical technique and stimulation of hepatocyte proliferation by combined partial liver resection and thymidine kinase—ganciclos in treatment. Gene Ther. 6(1):34-41 (1999)  Qi et al.; "Blockade of type β transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat"; Proc. Natl. Acad. Sci. USA, Vol. 96, March 1999, Medical Sciences, pp. 2345-2349  Remington's Pharmaceutical Services, Mack Publishing Company: Easton, PA. 18th Edition, pages 1303, 1304. and 1571.  Big. Ruiz et al.; "Gene therapy of viral hepatitis and hepatocellular carcinoma", Journal of Viral Hepatitis, 1999, 6, pp. 17-34  Themis M. et al. Enhanced in vitro and in vivo gene delivery using cationic agent completed retrovirus vectors, Gene Ther. 1998 Sept; 5(9):1180-6  Cecha of Therapocyte growth factor gene therapy of liver circhosis in rate: 1999 Nature Amorica Inc., Mal. 5. Na. 2-February. 1999, pp. 226-230  Verma LM- et al. Gene therapy - promises, problems and prospects. Nature 389/239-242.	j			ovir pre-treatment, Pharmacol Res. 40(5):451-7
to WHHL rabbit liver after improved surgical technique and stimulation of hepatocyte proliferation by combined partial fiver resection and thymidine kinase—gancielovir treatment. Gene Ther. 6(1):34-41 (1999)  Qi et al.; "Blockade of type β transforming growth factor signaling prevents liver fibrosis and dysfunction in the raf"; Proc. Natl. Acad. Sci. USA, Vol. 96, March 1999, Medical Sciences, pp. 2345-2349  Remington's Pharmaceutical Services. Mack Publishing Company: Easton, PA. 18th Edition, pages 1303, 1304. and 1571.  Ruiz et al.; "Gene therapy of viral hepatitis and hepatocellular carcinoma"; Journal of Viral Hepatitis, 1999, 6, pp. 17-34  Themis M. et al. Enhanced in vitro and in vivo gene delivery using cationic agent completed retrovirus vectors, Gene Ther. 1998 Sept; 5(9):1180-6  Leviet al., "Hepatocyte growth factor gene therapy of liver circlinosis in rate", 1999 Nature Amosica Inc., Vol. 5, No. 2, February, 1999, pp. 226-230  Verma L.M. et al. Gene therapy - promises, problems and prospects. Nature 389/239-242.		DB		
DE partial liver resection and thymidine kmase—ganciclovir treatment, Gene Ther, 6(1):34-41 (1999)  Quetal; "Blockade of type B transforming growth factor signaling prevents liver librosis and dysfunction in the rat"; Proc. Natl. Acad. Sci. USA, Vol. 96, March 1999, Medical Sciences, pp. 2345-2349  Remington's Pharmaceutical Services. Mack Publishing Company: Easton, PA. 18th Edition, pages 1303, 1304. and 1571.  Ruiz et al.; "Gene therapy of viral hepatitis and hepatocellular carcinoma"; Journal of Viral Hepatitis, 1999, 6, pp. 17-34  Themis M. et al. Enhanced in vitro and in vivo gene delivery using cationic agent completed retrovirus vectors, Gene Ther. 1998 Sept; 5(9):1180-6  [Peter of Page 1999, pp. 226-230]  DI Verma-L-M-er al. Gene therapy - promises, problems and prospects. Nature 389:239-242.	- 1	1	Pakkanen, et al., Enhanced plasma cholesterol lowering effect of re	trovirus-mediated LDL receptor gene transfer
Qi et al.; "Blockade of type \( \beta\) transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat"; Proc. Natl. Acad. Sci. USA, Vol. 96, March 1999, Medical Sciences, pp. 2345-2349  Remington's Pharmaceutical Services, Mack Publishing Company: Easton, PA. 18th Edition, pages 1303, 1304, and 1571.  Ruiz et al.; "Gene therapy of viral hepatitis and hepatocellular carcinoma"; Journal of Viral Hepatitis, 1999, 6, pp. 17-34  Themis M. et al. Enhanced in vitro and in vivo gene delivery using cationic agent completed retrovirus vectors, Gene Ther. 1998 Sept; 5(9):1180-6  Ucki et al., "Mepatocyte growth factor gene therapy of liver circlussis in-rate", 1990 Nature Amorica Inc., Mol. 5, Np. 2, February, 1999, -pp. 226-230  Verma 1-M-craft Gene therapy - promises, problems and prospects. Nature 389:239-242.	1	ļ		
DD rat": Proc. Natl. Acad. Sci. USA, Vol. 96, March 1999, Medical Sciences, pp. 2345-2349  Remington's Pharmaceutical Services, Mack Publishing Company: Easton, PA. 18th Edition, pages 1303, 1304. and 1571.  But et al.; "Gene therapy of viral hepatitis and hepatocellular carcinoma", Journal of Viral Hepatitis, 1999, 6, pp. 17-34  Themis M. et al. Enhanced in vitro and in vivo gene delivery using cationic agent completed retrovirus vectors, Gene Ther. 1998 Sept; 5(9):1180-6  Ucki et al., "Hepatocyte growth factor gene therapy of liver circlosis in rate": 1000 Nature Amorica Inc., Aid. 5.  No. 2-February. 1999. pp. 226-230  Verma I-M-et al. Gene therapy - promises, problems and prospects. Nature 389:239-242.		<u>FC</u>		
Remington's Pharmaceutical Services, Mack Publishing Company: Easton, PA, 18th Edition, pages 1303, 1304, and 1571.  Ruiz et al., "Gene therapy of viral hepatitis and hepatocellular carcinoma", Journal of Viral Hepatitis, 1999, 6, pp. 17-34  Themis M. et al. Enhanced in vitro and in vivo gene delivery using cationic agent completed retrovirus vectors, Gene Ther. 1998 Sept; 5(9):1180-6  Ucki et al., "Hopatocyte growth factor gene therapy of liver circhosis in rate", 1999 Nature Amorica Inc., Mol. 5.  No. 2. February, 1999, pp. 226-230  Ucrma_I-M-eral. Gene therapy - promises, problems and prospects. Nature 389:239-242.	1	•	Qi et al.; "Blockade of type β transforming growth factor signaling	prevents liver fibrosis and dysfunction in the
DE and 1571.  Ruiz et al.; "Gene therapy of viral hepatitis and hepatocellular carcinoma"; Journal of Viral Hepatitis, 1999, 6, pp. 17-34  Themis M. et al. Enhanced in vitro and in vivo gene delivery using cationic agent completed retrovirus vectors, Gene Ther. 1998 Sept; 5(9):1180-6  Levi et al. "Hepatocyte prowth factor gene therapy of liver circliosis in rate"; 1999 Nature Amosica Inc. Mol. 5.  No. 2-February-1999, pp. 226-230  Verma 1-M-crift Gene therapy - promises, problems and prospects. Nature 389:239-242.		; DD		
Ruiz et al.; "Gene therapy of viral hepatitis and hepatocellular carcinoma"; Journal of Viral Hepatitis, 1999, 6, pp. 17-34  Themis M. et al. Enhanced in vitro and in vivo gene delivery using cationic agent completed retrovirus vectors, Gene Ther. 1998 Sept; 5(9):1180-6  Level of Unit et al., "Hepatocyus growth factor gene therapy of liver circlinsis in rats": 1999 Nature Amosica Inc., Mal., 5.  D1 Verma LAM-et al. Gene therapy - promises, problems and prospects. Nature 389:239-242.		1	Remington's Pharmaceutical Services, Mack Publishing Company:	Easton, PA, 18th Edition, pages 1303, 1304.
DF 17.34  Themis M. et al. Enhanced in vitro and in vivo gene delivery using cationic agent completed retrovirus vectors, Gene Ther. 1998 Sept; 5(9):1180-6  Perody of Ucki et al. "Hopotocyte growth factor gene therapy of liver circlinsis in rate", 1999 Nature America Inc., Vol. 5.  No. 2. February. 1999. pp. 226-230  Verma L.Met al. Gene therapy - promises, problems and prospects. Nature 389:239-242.		DE	and 1571.	
DF 17.34  Themis M. et al. Enhanced in vitro and in vivo gene delivery using cationic agent completed retrovirus vectors, Gene Ther. 1998 Sept; 5(9):1180-6  Perody of Ucki et al. "Hopotocyte growth factor gene therapy of liver circlinsis in rate", 1999 Nature America Inc., Vol. 5.  No. 2. February. 1999. pp. 226-230  Verma L.Met al. Gene therapy - promises, problems and prospects. Nature 389:239-242.			Ruiz et al.; "Gene therapy of viral hepatitis and hepatocellular carc	inoma"; Journal of Viral Hepatitis, 1999, 6, pp.
DG Gene Ther. 1998 Sept; 5(9):1180-6  Yearly of Ucki et al., "Hopatocyte growth factor gene therapy of liver circlosis in rate", 1990 Nature Amosica Inc., Mal. 5.  No. 2-February. 1999, -pp. 226-230  DI Verma I-M-et al. Gene therapy - promises, problems and prospects. Nature 389:239-242.	1	DF		
DG Gene Ther. 1998 Sept; 5(9):1180-6  Yearly of Ucki et al., "Hopatocyte growth factor gene therapy of liver circlosis in rate", 1990 Nature Amosica Inc., Mal. 5.  No. 2-February. 1999, -pp. 226-230  DI Verma I-M-et al. Gene therapy - promises, problems and prospects. Nature 389:239-242.	not		Themis M. et al. Enhanced in vitro and in vivo gene delivery using	cationic agent completed retrovirus vectors,
DI Verma I-M-et al. Gene therapy - promises, problems and prospects. Nature 389:239-242.	$\bowtie$	DG		•
DI Verma I-M-et al. Gene therapy - promises, problems and prospects. Nature 389:239-242.	Alrendy	of	Ucki et al., "Hepatocyte growth factor gene therapy of liver circles	is in rate: 1999 Nature Amorica Lucalial.
DI Verma I-M- et al. Gene therapy - promises, problems and prospects. Nature 389:239-242.	record			
	1			
	<u> </u>	DI	Verma 1-M-et al. Gene therapy - promises, problems and prospect	s. Nature 389:239-242.
		<del> </del>		Dr. B. B. Lander
			part of the second	the state of the s
		ļ		
		)		
		-		
		1		
		-		
		1	:	
		<del></del>		
		1		
7)110 1	X-173198.1	1		

LA-173198.1

EXAMINER:

DATE CONSIDERED:

5/6/04

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

Information Disclosure Statement - Section 9 PTO-1449

Page 5 of 5